At Reflect Wellness and Aesthetics, the first care-delivery question is not which injection to choose. It is which organization will evaluate you, prescribe medication and handle problems after the consultation. Reflect describes its own Tennessee practice, with clinics in Murfreesboro and Franklin, alongside a national program staffed by independent providers through a partner platform. Those pathways share a website, but the published terms do not describe them as one clinical service. That distinction matters when deciding whom to contact about a prescription, a shipment or follow-up care.
This documentary review examines Reflect’s public documentation consulted October 19, 2026. The local offering is comparatively concrete: clinician-guided compounded injection programs, weekly dose-tier prices and monthly visits. The national offering documents an online assessment and potential home delivery, but leaves the platform, provider network, pharmacies and package prices unnamed in the consulted material. The review follows those handoffs rather than treating enrollment as proof of treatment. It also separates Reflect’s descriptions of its services from independently established clinical evidence; no credentials, pharmacy arrangements or patient outcomes were independently verified.
At a glance
- Two clinical pathways
- Reflect’s practice provides Tennessee clinic and Tennessee telehealth care. Independent providers assess national-program patients; Reflect says it does not prescribe in that program.Sources: [14]
- Local compounded injection prices
- Tennessee clinic cash-pay prices are $25–$125 per week for compounded semaglutide and $75–$175 per week for compounded tirzepatide, across six clinician-selected tiers each. Both list a $10 take-home fee.
- Follow-up structure
- Reflect advertises monthly visits and individualized adjustments within program tiers rather than changes on a fixed schedule.Sources: [13]
- National prescription handoff
- An assessment does not guarantee a prescription. If issued, national-program prescriptions are filled by a licensed 503A compounding pharmacy selected through the provider network.Sources: [14]
Start by identifying the treating practice
Reflect presents itself as a broader wellness practice, not solely a weight-management service. Its five stated categories are weight management, peptides, hormone therapy, aesthetics and IV therapy. The website says Dr. Brandon Hardin owns and leads the practice. It identifies Danelle Farmer, NP, in Murfreesboro as a board-certified nurse practitioner and Michelle Sloan, NP, in Franklin as a board-certified family nurse practitioner, both providing weight-management care. These are provider-published descriptions, not independent credential checks, and they do not establish which clinician would handle a particular appointment.
For Tennessee patients, the terms place clinic visits and Tennessee telehealth under the practice’s own licensed providers. Reflect also advertises medication delivery across Tennessee. Outside that pathway, the national program uses an independent clinical network through a partner telehealth platform; Reflect explicitly disclaims prescribing there or controlling those providers’ medical judgment. Before submitting health information, establish which pathway your booking enters and obtain the treating organization’s name. Our guide to clinicians and telehealth platforms explains why a website’s brand and the entity delivering medical care may differ.
What happens before a prescription
Reflect describes an initial consultation and health screen in which a licensed clinician reviews health history and goals and determines whether a program fits. The semaglutide page refers to baseline health screening at consultation under a labs heading, but it does not identify particular laboratory tests. That wording should not be read as a promise of a defined testing panel or proof that laboratory charges are included. The menu states that consultation is required before treatment, leaving the assessment—not the advertised weekly price—as the first clinical checkpoint.
The website’s terms require users to be at least 18 to use the site, book services or submit intake information. That is a site-access rule, not a complete medication eligibility standard. The consulted material does not establish Reflect-specific BMI thresholds, detailed contraindications or comprehensive screening criteria. For the national program, it expressly says completing an assessment does not guarantee a prescription. Useful preparation includes a current medication and supplement list, relevant health history and questions about testing costs. The first-consultation guide provides a framework without substituting for the treating clinician’s assessment.
The injection menu is more specific than a single starting price
Reflect documents compounded semaglutide as a clinician-guided GLP-1 injection program and compounded tirzepatide as a dual GLP-1 and GIP injection program monitored by a licensed provider. Its semaglutide page describes weekly self-administration and says the clinician explains how the medication is supplied and injected during consultation. Two additional Tennessee-only programs pair compounded medication with B12 and L-carnitine: SkinT uses tirzepatide, while Xtra Skinny uses semaglutide. Their branded names identify different advertised offerings, not evidence that adding those ingredients improves treatment outcomes.
The table preserves the local menu’s weekly units and tier conditions. These are Tennessee clinic cash-pay prices, not national-package quotes or established all-in totals. Reflect says the clinician selects the starting tier and reviews it at monthly visits. The standard semaglutide and tirzepatide pages each add a $10 take-home fee without establishing how often it applies. Semaglutide advertises up to 15% off with membership, while the main site says membership is optional; membership cost and maximum-discount conditions remain undocumented here. No monthly or annual total can be reliably derived from this menu.
| Program and presentation | Published weekly price | Conditions and fees |
|---|---|---|
| Compounded semaglutide; weekly self-administered injection | $25–$125/week | Six clinician-selected tiers; $10 take-home fee, frequency unspecified |
| Compounded tirzepatide; injection program | $75–$175/week | Six clinician-selected tiers; $10 take-home fee, frequency unspecified |
| SkinT: compounded tirzepatide paired with B12 and L-carnitine; weekly self-administered injection | $85–$185/week | Six clinician-selected tiers; Tennessee clinics only; monthly monitoring |
| Xtra Skinny: compounded semaglutide paired with B12 and L-carnitine; weekly self-administered injection | $35–$100/week | Five clinician-selected tiers; Tennessee clinics only; monthly monitoring |
The pharmacy handoff needs a named destination
Reflect states that it is not a pharmacy. It describes prescriptions as issued by licensed medical providers and filled by U.S.-licensed, FDA-registered pharmacies, including 503A compounding pharmacies. The semaglutide page specifies patient-specific prescriptions from a state-licensed 503A compounding pharmacy. National-program terms say the provider network selects the dispensing pharmacy. However, the consulted material does not name the dispensing pharmacies, partner platform or independent medical network. Those missing names prevent this review from tracing an actual prescription through a particular organization or independently checking the advertised arrangements.
Before payment, request the pharmacy’s name, contact details and the exact prescribed formulation, presentation and instructions. Also establish who answers questions when the prescription and supplied product do not appear to match. Our pharmacy-handoff guide outlines these responsibilities. FDA registration or a reference to regulated pharmacies does not mean Reflect or its compounded preparations are FDA approved. Compounded preparations do not undergo FDA premarket review for safety, effectiveness and quality. FDA recommends them when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy; nonapproval alone does not establish clinical inequivalence.
Delivery is offered, but the delivery process is not fully described
Reflect offers Tennessee telehealth with medication delivery and describes the outside-Tennessee pathway as an online assessment with home delivery where available. Its terms qualify national availability by state. That combination supports describing a delivery option, not universal access in every state. The consulted material supplies neither an admitted-state list nor firm clinical-review, dispatch or arrival timelines. It also does not identify a carrier or explain how lost or damaged shipments are handled. A reader should therefore confirm location eligibility and delivery arrangements before assuming that an online assessment can lead to a timely shipment.
For injectable medication, ask who supplies storage instructions, how temperature-sensitive shipments are packaged and which organization handles a delivery concern. Reflect’s consulted documentation does not establish its cold-chain procedures or replacement policy. FDA explicitly advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. The distinction between approval, dispatch and arrival is especially important here: a prescription decision does not establish when a usable product will reach the patient. Our delivery-timing guide helps organize those separate questions without promising a turnaround.
Monthly visits are documented; between-visit access is less clear
Reflect’s local weight-management page says monthly visits keep the plan aligned with how the patient is doing. It describes clinician adjustments within program tiers as individualized rather than tied to a fixed schedule. The semaglutide page likewise advertises monthly visits and ongoing monitoring, and the Tennessee combination-program pages list monthly clinician visits. This is a meaningful description of planned follow-up, but it does not establish appointment length, a standardized set of measurements or how quickly a patient can obtain an unscheduled clinical review. Those details should be confirmed for the specific program being purchased.
The national pathway requires a separate follow-up conversation because Reflect is not its prescribing practice. Ask which organization receives symptom reports, whether the same clinician reviews subsequent assessments and what happens when the prescriber is unavailable. The terms explicitly state that website forms, messages and booking tools are not monitored for urgent medical needs. No response-time or after-hours commitment is established in the consulted material. NIDDK describes follow-up as attention to treatment response and tolerability, not simply continued payment; the useful question is therefore what clinical access accompanies the recurring service, not merely whether another shipment can be ordered.
Additional products create additional care decisions
The Tennessee menu includes more than the compounded injection programs. B12 and L-carnitine are each listed at $10 per injection, available in person at Franklin and Murfreesboro and addable during consultation or follow-up without a separate appointment. A lipotropic injection is listed at $20 per injection under the same in-person arrangement; its page leaves the specific blend for discussion during consultation rather than enumerating it. These entries document optional products and access points. They do not show that the add-ons are included in a GLP-1 fee or establish additional clinical benefit.
Reflect also lists prescription phentermine tablets at $30 for 30 tablets, with clinician review and monitoring alongside the weight-management plan. That quantity should not be relabeled as a month’s supply. Its Tennessee-only compounded prescription ondansetron tablets cost $6.99 for 15 or $10.99 for 30, with appropriateness reviewed by the clinician. The practical delivery issue is who authorizes and monitors each additional medicine and whether it comes from the same pharmacy. Each extra product deserves a separate explanation of purpose, composition and cost rather than being treated as an automatic component of enrollment.
Get the service agreement before treating the quote as complete
Reflect describes its program as direct-pay rather than insurance-covered and says the clinician confirms the full plan cost, including any take-home fee, before treatment starts. However, the consulted material does not establish whether each quoted rate includes consultations, laboratory work, injection supplies or shipping. A weekly price is a pricing unit, not proof of weekly billing. National packages have separate, unspecified prices, and national payments use a third-party processor while clinic payments use in-clinic systems. The site says it does not store full payment-card details, but that statement does not resolve billing schedules or recurring-payment authorization.
The published terms direct readers to purchase- or booking-specific rules for cancellation, refunds and no-shows. They also identify themselves as an operational draft not yet reviewed by an attorney, and say separate clinical consents and agreements govern medical care. Consequently, this review cannot establish a minimum commitment, automatic-renewal arrangement or refund entitlement. Obtain those documents before paying, including what happens if no prescription is issued or delivery fails. Marketing-text consent is not a condition of purchase, and STOP is offered for opting out; ending marketing messages should not be confused with canceling a clinical service or payment agreement.
Questions & answers
Will a Reflect clinician handle my national telehealth assessment?
Not under the division described in Reflect’s terms. Its own practice handles Tennessee clinic and Tennessee telehealth services, while an independent network through a partner platform conducts national assessments. Reflect says it does not prescribe in the national program. Ask for the treating entity’s name, clinical contact route and follow-up arrangements before enrolling. The consulted documentation does not identify the platform or network by name.
Can I use the $25 weekly semaglutide price outside Tennessee?
The published $25–$125 weekly range applies to Tennessee clinic cash-pay compounded semaglutide, with six tiers selected by the clinician. It is not a national-program price. The page also lists a $10 take-home fee without specifying its frequency. National packages are priced separately, and their amounts are not established in the consulted material. Request a complete quote for your location and service pathway rather than applying the lowest local tier to a national order.
Does Reflect identify the pharmacy that will supply my medication?
The consulted material describes state-licensed 503A compounding pharmacies but does not name the dispensing pharmacies. National terms say the provider network selects the pharmacy after a prescription is issued. Reflect itself is not a pharmacy. Before paying, request the dispensing pharmacy’s identity and contact information, plus the exact formulation and presentation. The provider’s FDA-registration language should not be interpreted as FDA approval of the compounded preparation.
What help is documented between monthly visits?
Reflect documents monthly monitoring and individualized clinician adjustments, but the consulted material does not specify between-visit response times or after-hours coverage. Its terms say website forms, messages and booking tools are not monitored for urgent needs. Ask for the appropriate nonurgent clinical contact and the instructions for situations that cannot wait. National patients should obtain this information from the independent treating organization rather than assuming Reflect’s local clinic manages their care.
Is membership required, and does it fix my treatment price?
Reflect says membership is optional, never required. Its compounded semaglutide page advertises up to 15% off with membership, but the consulted material does not establish membership cost, qualification for the maximum discount or a price-lock promise. Local medication prices depend on the clinician-selected tier. Ask for both the membership agreement and a treatment quote showing how any discount applies, including whether additional charges remain separate.
Can I cancel and receive a refund if treatment does not proceed?
The consulted general terms do not establish that entitlement. They say the specific refund, cancellation and no-show terms presented at purchase or booking control, while separate clinical agreements govern care. National assessment also does not guarantee a prescription. Before payment, ask what is charged if prescribing is declined, what can be canceled after pharmacy processing and how delivery problems are resolved. Cancellation and refund eligibility are separate questions; neither should be assumed from the other.
Our assessment
Reflect’s strongest documented care pathway is its Tennessee practice: named local clinicians, an initial consultation, published compounded-injection price tiers and monthly follow-up. Its explicit separation of national prescribing from its own practice is also useful disclosure. The main limitation is that readers cannot fully trace the national handoff from assessment to named prescriber, pharmacy and ongoing support using the consulted documentation. Delivery procedures and purchase-specific financial terms likewise need confirmation. A practical next step is to obtain a written pathway-specific quote, the treating organization and pharmacy names, follow-up contact instructions and the cancellation agreement before paying. These documents would help distinguish an advertised service from a clearly assigned set of clinical and fulfillment responsibilities. This review does not establish Reflect’s treatment outcomes or the effectiveness of its compounded formulations and combinations.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Reflect Wellness and Aesthetics — weight loss/programs/phentermine ↗
- Reflect Wellness and Aesthetics — weight loss/programs/lipotropic injection ↗
- Reflect Wellness and Aesthetics — weight loss/programs/glp 1 t ↗
- Reflect Wellness and Aesthetics — weight loss/programs/skint ↗
- Reflect Wellness and Aesthetics — weight loss/programs/xtra skinny ↗
- Reflect Wellness and Aesthetics — weight loss/programs/l carnitine injection ↗
- Reflect Wellness and Aesthetics — official website ↗
- Reflect Wellness and Aesthetics — weight loss/programs/ondansetron ↗
- Reflect Wellness and Aesthetics — weight loss/programs/glp 1 s ↗
- Reflect Wellness and Aesthetics — weight loss/programs/b12 injection ↗
- Reflect Wellness and Aesthetics — weight loss/programs ↗
- Reflect Wellness and Aesthetics — terms of service ↗